Objectif In the last 15 years the advances in understanding the molecular mechanisms of pain have been spectacular. However, despite the >200 genes identified and the dramatic insights on transduction and transmission of nociceptive signals, very little has changed in the diagnosis and treatment of pain, at least in terms of analgesic drugs. Therefore, pain remains a major burden for the society (chronic pain alone costs the EU >€250 bns/yr). The reason is that pain is not a pattern of gene expression, but a state of neuronal activity. Therefore, the translation of mechanistic insights into effective treatments will depend critically on a better understanding of the electrophysiological changes that occur. For this reason, the European Federation of Neurological Society has called for a particular effort to identify reliable laboratory measures of pain, and having an objective biomarker for pain quantification and patient stratification would constitute a major breakthrough in medicine. To date, this need has not been satisfied. The project has two main objectives: (1) Developing neurophysiological biomarkers of pain perception: the main aim being quantification of spontaneous pain for patient management and clinical trials. (2) Developing neurophysiological biomarkers of the susceptibility to develop chronic pain: the main aim being patient stratification, development of prevention strategies, and personalised medicine for pain. We will apply novel analysis techniques to the neurophysiological information obtained using a range of techniques from a large number of healthy volunteers and patients with different types of chronic pain. Importantly, we will longitudinally study patients at high risk of developing chronic pain. We are fully confident that these goals - early diagnosis, identification of high risk patients and facilitating the development of new efficacious treatments through useful clinical trials - will positively impact the well-being of chronic pain patients. Champ scientifique medical and health scienceshealth sciencespersonalized medicine Mots‑clés personalized medicine patient stratification chronic pain neurophysiology Programme(s) H2020-EU.1.1. - EXCELLENT SCIENCE - European Research Council (ERC) Main Programme Thème(s) ERC-CoG-2014 - ERC Consolidator Grant Appel à propositions ERC-2014-CoG Voir d’autres projets de cet appel Régime de financement ERC-COG - Consolidator Grant Institution d’accueil FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA Contribution nette de l'UE € 1 181 995,86 Adresse VIA MOREGO 30 16163 Genova Italie Voir sur la carte Région Nord-Ovest Liguria Genova Type d’activité Research Organisations Liens Contacter l’organisation Opens in new window Site web Opens in new window Participation aux programmes de R&I de l'UE Opens in new window Réseau de collaboration HORIZON Opens in new window Coût total € 1 181 995,86 Bénéficiaires (2) Trier par ordre alphabétique Trier par contribution nette de l'UE Tout développer Tout réduire FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA Italie Contribution nette de l'UE € 1 181 995,86 Adresse VIA MOREGO 30 16163 Genova Voir sur la carte Région Nord-Ovest Liguria Genova Type d’activité Research Organisations Liens Contacter l’organisation Opens in new window Site web Opens in new window Participation aux programmes de R&I de l'UE Opens in new window Réseau de collaboration HORIZON Opens in new window Coût total € 1 181 995,86 UNIVERSITY COLLEGE LONDON Participation terminée Royaume-Uni Contribution nette de l'UE € 445 829,14 Adresse GOWER STREET WC1E 6BT London Voir sur la carte Région London Inner London — West Camden and City of London Type d’activité Higher or Secondary Education Establishments Liens Contacter l’organisation Opens in new window Site web Opens in new window Participation aux programmes de R&I de l'UE Opens in new window Réseau de collaboration HORIZON Opens in new window Coût total € 445 829,14